

## **PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference**

PETACH TIKVA, Israel, Feb. 28, 2024 — PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26<sup>th</sup> Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 - 14, 2024.

### **Barclays 26<sup>th</sup> Annual Global Healthcare Conference Fireside Chat**

Date: Thursday, March 14, 2024  
Time: 7:30 - 7:55 AM ET

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Barclays representative.

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX<sub>100</sub> is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

### **Contacts:**

PolyPid Ltd.  
Ori Warshavsky  
COO - US  
908-858-5995  
IR@Polypid.com

### **Investors:**

Brian Ritchie  
LifeSci Advisors  
212-915-2578

britchie@lifesciadvisors.com

